Table 4.

Survival Comparison for GC, M-VAC, ITP, and AG-ITP Regimens

Variable	Treatment
	GC4,5		M-VAC27		ITP12		AG-ITP
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
No. of patients	203		133		44		60
Survival, months
6	82	NR	83	77 to 90	95	89 to 100	88	77 to 94
12	58	52 to 65	54	46 to 63	66	52 to 80	77	64 to 85
18	37	NR	37	28 to 45	54	40 to 69	45	32 to 57
24	25	19 to 31	30	22 to 37	44	29 to 59	33	22 to 45
Median survival, months	14		13.4		20		16.4
Progression-free survival, months
Median	7.7		9.6		9.6		12.1
95% CI	6.8 to 8.8		8.0 to 11.0		6.5 to 16.3		9.0 to 14.8
Follow-up, months
Median	NR		39.8		28		76.4
Range	NR		0.3-129		19-43		65-108

Abbreviations: M-VAC, methotrexate, vinblastine, doxorubicin, cisplatin; GC, gemcitabine, cisplatin; ITP, ifosfamide, paclitaxel, cisplatin; AG-ITP, doxorubicin, gemcitabine, ifosfamide, paclitaxel, cisplatin; NR, not reported.